HIMS 全部观点

已加载 20 条观点条目,其中 0 条方向发生变化

在已加载记录中筛选
Schwab Network发布 2026-11-18
《Wednesday's Final Takeaways: Gold at 52-Week Lows, Housing Market Mixed》
$HIMS中性
AI 摘要 · HIMS 推出 Peptides Plus,包含五种联合疗法,有望在肽类需求上升之际吸引传统远程医疗之外的新客户并带来经常性收入;但首批疗法均未获 FDA 批准,HIMS 表示安全性、有效性和剂量仍不确定,监管与科学风险可能实质性威胁其增长计划。

Hims&Hers 可能错过了“多肽热潮之夏”,但随着它推出新的“Peptides Plus”平台,提供五种组合疗法,针对从精力与恢复到细胞健康的各种需求,一个“多肽热潮之冬”可能即将到来。

Hims&Hers may have missed out on the " hot peptide summer," but there may be a " hot peptide winter" coming, as it launches its new "Peptides Plus" platform offering five combination therapies targeting everything from energy and recovery to cellular health.

这一举措出台之际,多肽的需求正在上升,但这里存在一个重大障碍。最初的治疗方案均未获得美国食品药品监督管理局(FDA)的批准,公司自己也承认,关于其安全性、有效性和合适剂量,仍有很多需要了解。

This move comes at a time when demand for peptides is increasing, but there is a major obstacle here . None of the initial treatments are approved by the Food and Drug Administration (FDA), and the company itself acknowledges that there is still much to learn about their safety, effectiveness, and appropriate dosages .

Verified Investing发布 2026-11-17
《MAJOR EARNINGS FOR NVIDIA (Silver Bottom?)》
$HIMS看涨
AI 摘要 · HIMS 自 5 月前不久起处于下跌趋势,尽管业绩尚可,股价仍下跌且仍在下跌;说话者只会在其跌至约 18 美元时买入,视其为潜在支撑区域。

所以,在市场整体小幅反弹的情况下,我在找一些可能下跌且位置稍低的标的,那就是HIMS。从今年5月之前一路延伸过来,有一条漂亮的下降趋势线,穿过这里,穿过这里,然后最终在下方寻找潜在支撑区域。

So with the markets generally kind of bouncing a little bit, I'm looking at something that might fall and is a little lower and that's HIMS HIMS. You have a nice downs sloping trend line from all the way back here just before May of this year coming through here coming through here and then finally looking for an area for potential support down here.

《NVDA Fallout: Where Is the Smart Money Going? | Market Pulse Nov. 13, 2026》
$HIMS看跌
AI 摘要 · HIMS 曾长期上涨,但在模糊记得的账户相关问题之后,连续数周下跌,并在衰竭缺口处跳空低开;说话者得出结论,它尚未恢复。

我们来看看“Hems”这家公司。它叫“Hems & Hers Health”。现在看这张图,不是吗?很明显,这张图已经向上趋势了很长时间。他们遇到了账户之类的一些问题。我记不清了。

但看看那连续数周的下跌,直到该股最终跳空低开,那是一个衰竭缺口。它真的没能恢复,对吧?

Let's take a look at the "Hems" company. It's called " [17:18] Hems & Hers Health". Now look at this [17:21] graph, don't you? It is clear that [17:24] this chart has been trending upwards for a long time [17:27] .

They encountered some problems with the accounts or something like that [17:29] . I can't remember. But [17:32] look at all those consecutive weeks of [17:35] decline, until the stock eventually gapped down [17:37] , and that was an exhaustion gap. He [17:39] really couldn't recover, did he?

Parkev Tatevosian, CFA发布 2026-11-13
《Why Is Hims Stock Crashing, and is it a Buying Opportunity?》
$HIMS看涨
AI 摘要 · HIMS 仍是买入机会,但他的信心已从中等降至低,原因是费用增速快于收入:G&A 几乎翻倍至 1.515 亿美元,营业利润从 1180 万美元降至 -6600 万美元,经营现金流从 2.39 亿美元降至 1.19 亿美元,因此约 18% 的下跌是合理的。尽管收入增长 49%、订阅用户增长 13%、每订阅用户收入提高 30%,但在 19 美元价位,该股相对他略高于 22 美元的合理价值以及 25.4 倍的远期市盈率仍被低估。

Hems & Hers 公布了季度财务业绩,令股市投资者感到失望。营收增长了49%,订阅用户增长了13%,但费用也增加了,现金流则大幅下降。

Hems & Hers announced quarterly financial results that disappointed investors in the stock market. Revenues increased by 49% and subscribers by 13%, but expenses also increased and cash flow decreased significantly.

投资者惩罚了这只股票,在公司公布这些数据后的第二天,股价下跌了约19%。所以我想分享一下我对 Heams & Hers 股票的评级,我认为这次股价下跌后是否构成了买入机会,以及我对该公司公允价值的估计。

Investors punished the stock, which fell by about 19 % the day after the company announced these figures. So I wanted to share my rating of Heams & Hers stock, whether I think this represents a buying opportunity after the price drop , and what my estimate of the company's fair value is.

他说在等
电话会议记录中对一般及行政费用(G&A)为何近乎翻倍的解释
成本上升与收购相关,而非结构性问题
下一次财报电话会议记录
支持买入逻辑
《Hims & Hers Collapses 30% In a Week》
$HIMS看涨
AI 摘要 · HIMS 在令人失望的季度后下跌 18%:订阅用户环比减少约 10 万,受品牌 GLP-1 产品结构影响,毛利率从 83% 降至 57%,第四季度营收指引小幅下滑,全年调整后 EBIT 指引被下调。说话者并未卖出,仍认为 HIMS 是值得持有 5-10 年的优秀公司,依据是其更高定价的订阅、TRT 与肽类策略以及类似 Costco 的健康订阅模式,管理层把希望押在 2027 年第一季度;短期订阅用户增长与竞争仍存疑问,下一季度指引很重要。

他和他妻子的公司周一公布了财报,周二盘后交易中,两人的股票下跌了18%。投资者不喜欢他们在财报中听到的内容。从很多方面来看,这份财报确实令人失望。订阅用户数环比下降。毛利率继续承压。

而且管理层表示,他们实际上并没有花那么多钱去获取那些新客户。这就是增长真正放缓的原因。

Shares of his and hers are down 18% in late trading on Tuesday after their company reported earnings on Monday. The investors did not like what they heard from the earnings report.

In a lot of ways, the report was really disappointing. The number of subscribers was down quarter over quarter. Gross margins continued to be under pressure. And management said that they were actually not spending as much to bring in those new customers. That's why growth really slowed.

他说在等
下一季度关于盈利性获客与增长的指引
恢复以盈利性增长为前提的获客
下一季度下一次财报电话会/指引
支持长期持有的论点
The Motley Fool发布 2026-11-10
《Stock Market Update: Rising Rates & Falling Stocks》
$HIMS中性
AI 摘要 · HIMS是一个好坏参半的判断:季度增长跃升至49%,部分来自收购,估值倍数相对合理,每用户收入从两个季度前的80美元升至105美元;但利润率持续下滑,随着营销收缩,用户数减少约10万至279万,同时竞争加剧、模式依赖营销。一种看法是它太难、已放弃;另一种看法是在10年视角下近期噪音无关紧要,并看好其计划中的美国产肽类产品。

Hims and Hers 过去一个月下跌了约 40%。他们是转向 AI 云了吗?还是说,对,他们需要,他们需要做那个 Allirds 转型。对,那大概应该,他们正在招聘大量 AI 人员。

只是还没在他们的产品里看到这一点。不过他们今天大幅下跌,截至我们录制时大约跌了 18%。

him and hers down about 40% in the past month. Did they pivot to uh AI cloud or Yeah, they need to Yeah, they need to do the uh the Allirds pivot. Yeah, that should probably They're hiring a lot of AI people. um just haven't seen that in in their products yet.

Uh but big move down for them today about 18% as we're recording right now.

Schwab Network发布 2026-11-10
《HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus》
$HIMS中性
AI 摘要 · 在意外亏损、营收与订阅用户数双双不及预期、指引低于市场共识之后,HIMS 下跌 13.5% 至约 19 美元,年初至今跌幅接近 40%。说话者预计其将在当前水平附近企稳,20 美元为主要支撑位,并卖出一份 12 月虚值看跌期权价差;他认为增长将持续但放缓,肽类业务的利好正在消退,两位数增长可能已经结束,但公司本身依然稳健。

我们来看一下 Hims and Hers 的走势图。这家医疗健康公司本季度意外转为亏损,并收窄了全年销售展望,股价因此承压。

Let's focus on the chart for Hims and Hers. Shares are under pressure after the healthcare company swung to a surprised loss for the quarter and narrowed its fullear sales outlook.

这是我们在一年走势图上看到的情况。它已经回落了相当多。Hims and Hers 目前下跌约13.5%,股价在19美元出头。所以这是今天早盘交易的焦点。

So here is a look at what we're seeing on the one year. It's come off quite considerably. We're down about 13.5% trading at $19 and change on him and hers. So this is the focus of the morning trade.

The Motley Fool发布 2026-11-05
《Market Crash Live: Why AI Stocks Are Plunging & What We're Doing Now》
$HIMS看涨
AI 摘要 · 即使AI支出停止,HIMS也不受影响,因此其投资逻辑未变,而股价已明显变得更便宜;近期走势属于波动性的价格行为,而非基本面发生变化。

而这只是因为几个波动较大的股票,Hims and Hers 和 Robin Hood,你知道,它们会暂时上下波动。我记得 Hims and Hers 昨天涨了13%。

And that's just because of a couple of volatile names, Hims and Hers and uh and Robin Hood, which, you know, they they go up and down temp. I think Hims and Hers was up 13% yesterday.

就像没人在想,嘿,这对 Hims and Hers 或 Zeta Global 是好事吗?他们只是要卖出 beta。

Like nobody's thinking about, hey, is this good for him and hers or Zeta Global? they're just going sell beta

《Hims & Hers: The 10x Stock You Can't Ignore》
$HIMS看涨
AI 摘要 · HIMS 被严重低估:它在美国庞大的医药市场中占据领先地位,已观察到的销售份额达 51%,正在拓展产品线并推进国际化,其肽类业务到 2027 年底可能突破十亿美元。营收约 26 亿美元,管理层指引 2026 年下半年年增长 50%,肽类业务有望在几年内将营收推升至 50–60 亿美元;目前市销率接近 1 倍,这样的增长理应获得更高倍数。风险在于管理层战线拉得过宽,不过他仍支持这支团队。

在我看来,对投资者来说拥有巨大机会的公司之一就是 Hims & Hers。这家公司正试图彻底改变世界上最大的行业之一,也就是医疗行业和制药行业。

In my opinion, one of the companies that has huge opportunities for investors is Hims& Hers. This company is trying to radically change one of the largest industries in the world, namely the medical industry and the pharmaceutical industry.

仅在美国,制药行业的规模就约为4000亿美元。从我现在看到的情况来看,HimsandHers 的市值只有约64亿美元。这家公司的价值在未来10年或20年里,可能不只是增长10倍,而是有可能增长100倍。

The pharmaceutical industry is worth about $400 billion in the United States alone. From what I see now, HimsandHers has a market capitalization of only about $6.4 billion. This is a company whose value could increase not just 10 times, but potentially 100 times in the next 10 or 20 years.

他说在等
11月9日财报中的第三季度业绩
确认未来增长催化剂的积极第三季度业绩
11月9日第三季度财报
支持被低估的论点
Parkev Tatevosian, CFA发布 2026-10-18
《Hims Is Reaching 3 Million Member Milestone》
$HIMS看涨
AI 摘要 · HIMS 是中等信心的买入标的:营收增长出色,管理层 65 亿美元营收目标看起来可以实现,但利润率正在收缩,ROIC 从约 35% 降至 -8.4%。估值合理(DCF 26.90 美元 vs 27.72 美元),风险高于平均水平;他正在等待更低的入场点,以长期持有。

Hims & Hers 的股票是我近年来密切关注的一只,我认为它是一个非常有前景的投资机会。这只股票的价格一直波动较大。它经历了显著的变化,与一些最大合作伙伴发生了诉讼,营收增长迅猛,会员增长也在加速。

Hims & Hers stock is one I have been watching closely in recent years as a very promising investment opportunity. The stock price has been volatile. It has undergone significant changes, lawsuits with some of its biggest partners, revenue growth is soaring, and membership growth is accelerating .

The Motley Fool发布 2026-10-14
《4 Stocks to Buy Now and Hold for the Next Decade》
$HIMS看涨
AI 摘要 · HIMS 是一只看涨但风险较高的长期持仓:它正在颠覆医疗健康行业,自2020年以来复合年增长率达60%,并预测2026年下半年营收同比增长50%,通常能超预期;与 Lilly/Novo 的合作使其趋于稳定。其 AI/数据平台有望成为医疗健康领域的核心数据仓库。按3倍市销率估值,忽略了盈利能力,计划持有至2030年。

好,我们接着聊聊风险稍高一些的公司。我们可能把Mercado Libre放在了风险较高的一边,但它大概和Hems & Hers相当,后者是我想聊的第三只股票。

Okay, let's move on to talking about slightly more risky companies. We may have put Mercado Libre on the riskier side, but it 's probably on par with Hems & Hers, which is the third stock I wanted to talk about.

Hems & Hers是正在以多种方式革新医疗健康的公司之一。它让获取服务变得容易得多,因为你通过互联网或应用程序获取服务,与医生沟通,而不是真的去他的诊所、提供保险信息,然后去药房。

如果你像我们一样有孩子,这极其烦人,不是吗?尤其是对于普通的小毛病。所以,他们目前还没有覆盖所有科室,但想想他们10年后的位置,届时他们会从今天的五六个科室,扩展到也许覆盖大部分经常需要的需求。

Hems & Hers is one of the companies that is revolutionizing healthcare in many different ways. It makes accessing services really easier because you access them via the internet or an app, and you communicate with the doctor instead of actually going to his clinic, providing your insurance, and then going to the pharmacy.

If you have children like us, it's extremely annoying, isn't it? Especially for ordinary things. So, they don't cover all disciplines right now, but think about their position 10 years from now, when they will move from five or six disciplines today to perhaps most of the needs that are constantly required.

《Why I'm Betting Big on These 5 Growth Stocks》
$HIMS看涨
AI 摘要 · Hims and Hers 具备强劲的长期增长潜力;在监管和解与产品组合扩张之后,公司指引 2026 年下半年营收增长 50%。

说到那些还有大量增长空间的公司,Hims and Hers在2026年开局艰难,但2026年下半年,他们的指引是营收将增长50%。所以,如果我们看他们过去3年的复合年增长率,是54%,股票相当便宜。

企业价值与销售额之比约为2.8。这可能会大幅提升远期市盈率,达到81倍。对于Hims and Hers,我们目前还不关注盈利能力,但让我们看看过去一年左右发生了什么。

Speaking of companies that have a lot of growth runway ahead, Himson and Hers had a tough start to 2026, but the second half of 2026, their guidance is that they're going to grow revenue at 50%.

So, if we look at their component annual growth rate over the past 3 years, 54%, stocks pretty cheap. Enterprise value to sales about 2.8. That could significantly increase forward price earnings multiple 81.

We're not focused on profitability yet for his and hers, but let's look at what's happened over the past year or so.

他说在等
2026年下半年的营收增长
管理层指引的50%增长
2026年下半年财报
若实现则支撑看多逻辑;若增长未达指引则削弱该逻辑
The Motley Fool发布 2026-10-01
《The Truth About Hims & Hers Stock: A Deep Dive》
$HIMS中性
AI 摘要 · HIMS 属于高风险投机性买入标的,巨大的潜在市场规模与超过 50% 的增长潜力,与激烈竞争、监管不确定性及利润率承压风险相互抵消。

Hims & Hers 是市场上讨论度最高的股票之一,同时也是波动性最大的股票之一。过去五年该股上涨了 250%,但如果看过去一年,该股下跌了约 50%。公司内部正在发生很多事情。

Hims & Hers is one of the most talked-about stocks in the market. It is also one of the most volatile stocks . The stock has risen by 250% over the past five years , but if you look at it over the past year, the stock has fallen by about 50%. There's a lot going on inside the company.

Schwab Network发布 2026-09-18
《40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"》
$HIMS看涨
AI 摘要 · HIMS 估值偏低、具备上行潜力;其平台模式可从任何胜出的 GLP-1 药物中获取价值,随着市值增长,做空压力将逐步减弱。

我想谈谈“Hems & Hers Health”这家公司。这是另一个备受关注的名称,尤其是在社交媒体上。它是一只波动较大的股票,但似乎正处于过渡阶段,我很想知道你对它在这个领域所扮演角色的看法,以及你对这家公司的总体看法。

I want to talk about the company "Hems & Hers Health". This is another name that is attracting a lot of attention, especially on social media. It's a volatile stock, but it seems to be in a transitional phase, and I'm interested to know your opinion on its role in this area, and your general opinion of the company .

Parkev Tatevosian, CFA发布 2026-09-16
《Is Hims & Hers Stock a Buy Right Now in September? | HIMS Stock Analysis》
$HIMS看涨
AI 摘要 · 对于风险承受能力较高的长期投资者而言,HIMS 因增长前景强劲且估值合理而值得买入。

Hims & Hers 管理层向投资者重申了其长期业绩指引。管理层预计,到2030年营收至少达到65亿美元,调整后息税折旧摊销前利润达到13亿美元。

Hims & Hers management team reiterated its longer-term guidance to investors. The management team is forecasting at least $6.5 billion in revenue by 2030 and $1.3 billion in adjusted earnings before interest, taxes, depreciation, and amortization.

但这是否意味着 Hims & Hers 的股票对长期投资者来说是一个买入机会?因此,到2030年营收至少达到60亿美元,将是其最近12个月营收总额的两倍多。在这一时期,Hims & Hers 报告的营收为26亿美元。

这较2020年的约2.5亿美元有所增长。这一直是全球增长最快的公司之一。

But does this make Hims & Hers stock a buying opportunity for long-term investors? So, revenue of at least $6 billion by 2030 would be more than double their most recent trailing 12-month total.

In that period, Hims & Hers reported $2.6 billion in revenue. That's up from around $250 million in 2020. This has been one of the fastest-growing companies in the world.

他说在等
调整后EBITDA到2030年超过10亿美元
若实现,将改善盈利能力和利润率
到2030年未来财务报告
支持关于盈利能力改善的看多论点
《The Hims & Hers Australia Strategy: Why It Matters for Investors》
$HIMS看涨
AI 摘要 · HIMS是一个高增长的非对称投资案例;若成为全球医疗需求聚合者,其价值可能增长10至100倍。

作为美国领先的远程医疗公司,对 Hims & Hers 来说可能是一个 10 倍的机会,甚至更大,但成为全球远程医疗公司——无论你身在何处,都能回答你所有问题的地方——才是医疗保健和 Hims & Hers 真正巨大的机会所在。

Being a leading telehealth company in the US could be a 10x, maybe even a bigger opportunity for Hims & Hers, but beating being the global telehealth company where you go to answer all your questions no matter where you are in the world is really where the massive opportunity is for healthcare and for Hims & Hers.

Financial Education发布 2026-08-24
《This Stock will make us RICH🤑AF》
$HIMS中性
AI 摘要 · HIMS面临频繁的负面消息,持有需要坚定信念以避免被震出局。

第一,我们将在本视频中讨论Hims股票,好吗?有一些关于Hims的消息传出来。股价大幅下跌。我想谈谈这个。

Number one, we're going to discuss Hims stock in this video, okay? There was some news that came out in regards to Hims. Stock went down heavy. I want to talk about that.

Hims股票今天在这里遭到重创,下跌约8%,对吧?对Hims股票来说是艰难的一天。在我观察名单上的股票中,你知道,4000xstocks.com,这是今天表现最差的。

Hims stock got hammered here today, down 8% roughly, right? Tough day for Hims stock. Of the stocks on my watchlist, you know, 4000xstocks.com, that was the worst performer here today.

《4 Incredible Stocks I Love Today》
$HIMS看涨
AI 摘要 · Hims & Hers是一只长期成长股,潜力强劲,其营收增长重新加速、订阅用户增长以及利润率扩张机会为其提供了支撑。

Hims & Hers,尽管今年经历了这一切,实际上今年仍下跌近 20%,但你可以看到股价在 2 月底触底。自那以来,上涨近 100%,仅小幅回调。他们在 7 月初的交易价格接近每股 40 美元。

所以,自那以来,下跌约 25%。这是一只波动性很大的股票。所以,投资者需要记住这一点。

Hims & Hers, as for everything that it has gone through this year, is actually still down almost 20% for the year, but you can see shares bottomed in late February. Since then, up nearly 100% pulled back just a little bit.

They were trading at nearly $40 per share in early July. So, since then, down about 25%. Very volatile stock. So, something to keep in mind for investors.

继续看更早 →
其他股票的全部观点条目
把 $HIMS 加入我的股票30 天完整试用
开始试用